Doxorubicin liposomal is a cancer medication that interferes with the growth and spread of cancer cells in the body.

Doxorubicin liposomal is used to treat ovarian cancer, AIDS-related Kaposi’s sarcoma, and multiple myeloma.

Doxorubicin liposomal may also be used for purposes not listed in this medication guide.

Submit your review

Create your own review

Average rating:  
 0 reviews
  • Doxil, Lipodox, Lipodox 50
  • Get emergency medical help if you have signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat.

    Some side effects may occur during the injection. Tell your caregiver right away if you feel dizzy, nauseated, light-headed, sweaty, or have a headache, chest tightness, back pain, trouble breathing, or swelling in your face.

    Call your doctor at once if you have:

    pain, redness, swelling, blistering, or peeling skin on your hands or feet;
    feeling short of breath (even with mild exertion), swelling, rapid weight gain;
    fever, chills, body aches, flu symptoms;
    white patches or sores inside your mouth or on your lips;
    easy bruising, unusual bleeding (nose, mouth, vagina, or rectum), purple or red pinpoint spots under your skin; or
    pale skin, feeling light-headed or short of breath, rapid heart rate, trouble concentrating.
    Doxorubicin liposomal may cause your urine to turn a reddish-orange color. This side effect by itself is usually not harmful. However, call your doctor if you also have upper stomach pain, clay-colored stools, or jaundice (yellowing of your skin or the whites of your eyes).

    Common side effects may include:

    tired feeling;
    loss of appetite, nausea, vomiting;
    constipation, diarrhea; or
    temporary hair loss.
  • Usual Adult Dose for Ovarian Cancer 50 mg/m2 IV at an initial rate of 1 mg/min to minimize the risk of infusion reactions. If no infusion-related adverse events are observed, the rate of infusion can be increased to complete administration of the drug over one hour. The patient should be dosed once every four weeks, for as long as the patient does not progress, shows no evidence of cardiotoxicity, and continues to tolerate treatment. A minimum of four courses is recommended because median time to response in clinical trials was four months.